Publication | Closed Access

Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: Is there a clinical benefit?

UrologyGenitourinary CancerMedicineLow-dose PrednisolonePharmacotherapyClinical BenefitCancer TreatmentProstatic DiseaseOncologyFirst-line Docetaxel